What Will Alpine Immune Sciences Inc (NASDAQ: ALPN) Be Like After It Jumps -12.52% From Its Highs?

During the last session, Alpine Immune Sciences Inc (NASDAQ:ALPN)’s traded shares were 1.65 million, with the beta value of the company hitting 1.17. At the end of the trading day, the stock’s price was $38.11, reflecting an intraday loss of -2.81% or -$1.1. The 52-week high for the ALPN share is $42.88, that puts it down -12.52 from that peak though still a striking 82.39% gain since the share price plummeted to a 52-week low of $6.71. The company’s market capitalization is $2.50B, and the average intraday trading volume over the past 10 days was 1.1 million shares, and the average trade volume was 1.14 million shares over the past three months.

Alpine Immune Sciences Inc (NASDAQ:ALPN) trade information

Alpine Immune Sciences Inc (ALPN) registered a -2.81% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -2.81% in intraday trading to $38.11, hitting a weekly high. The stock’s 5-day price performance is 1.76%, and it has moved by 3.96% in 30 days. Based on these gigs, the overall price performance for the year is 393.65%. The short interest in Alpine Immune Sciences Inc (NASDAQ:ALPN) is 5.61 million shares and it means that shorts have 4.74 day(s) to cover.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Alpine Immune Sciences Inc (ALPN) estimates and forecasts

Statistics show that Alpine Immune Sciences Inc has underperformed its competitors in share price, compared to the industry in which it operates. Alpine Immune Sciences Inc (ALPN) shares have gone up 235.18% during the last six months, with a year-to-date growth rate less than the industry average at -175.00% against 8.20. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -50.00% this quarter and then drop -55.60% in the quarter after that. In the rating firms’ projections, revenue will decrease -73.50% compared to the previous financial year.

Revenue for the current quarter is expected to be $3.52 million as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to $3.49 million by the end of Jun 2024.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 24.56%. While earnings are projected to return -170.51% in 2024.

ALPN Dividends

Alpine Immune Sciences Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Alpine Immune Sciences Inc (NASDAQ:ALPN)’s Major holders

Alpine Immune Sciences Inc insiders own 4.63% of total outstanding shares while institutional holders control 91.20%, with the float percentage being 95.63%. Decheng Capital Management III (Cayman), LLC is the largest shareholder of the company, while 183 institutions own stock in it. As of Jun 29, 2023, the company held over 6.71 million shares (or 13.63% of all shares), a total value of $68.96 million in shares.

The next largest institutional holding, with 4.69 million shares, is of RA Capital Management, L.P.’s that is approximately 9.53% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $48.23 million.

Also, the Mutual Funds coming in first place with the largest holdings of Alpine Immune Sciences Inc (ALPN) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Jun 29, 2023 indicates that Vanguard Total Stock Market Index Fund owns about 0.85 million shares. This amounts to just over 1.73 percent of the company’s overall shares, with a $8.76 million market value. The same data shows that the other fund manager holds slightly less at 0.73 million, or about 1.49% of the stock, which is worth about $9.02 million.